10/19/2025

NETRIS Pharma to present the IMMUNONET abstract at the 2025 ESMO in Berlin

Reading : 5 min

IMMUNONET : A Proof-of-Concept Phase II evaluating NP137 as add-on therapy in solid tumors treated with standard immunotherapies: interim analysis of primary and secondary refractory cohorts FPN 966.

The NETRIS Pharma’s team presents the below abstract at the ESMO in Berlin in October 2025 :

right click on the image to open it in a new tab, or to save it